Pharmacy Times

JULY 31, 2023

The trial was recommended to continue to analyze event-free survival rates, but current results are encouraging for treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Chemotherapy 65

Chemotherapy 65

Pharmacy Times

APRIL 18, 2023

Study authors determined that prevention or mitigation of myelotoxic events that destroy bone marrow can potentially lessen myelosuppression in patients with ES-SCLC.

Chemotherapy 65

Chemotherapy 65

European Pharmaceutical Review

DECEMBER 7, 2022

In addition, A Phase III trial of Ivonescimab plus chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutated advanced non-squamous NSCLC that failed in prior epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) therapy is ongoing. percent and a median progression-free survival (mPFS) of 8.2

Chemotherapy 98

Chemotherapy 98

pharmaphorum

SEPTEMBER 21, 2020

Data from the phase 3 ASCENT study showed Trodelvy (sacituzumab govitecan) significantly extended overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared with standard chemotherapy in TNBC patients with brain metastases treated with at least two therapies. in the chemotherapy arm.

Chemotherapy 91

Chemotherapy FDA 91

European Pharmaceutical Review

MARCH 21, 2023

The landmark trial has demonstrated event-free survival (EFS), the primary endpoint, that is superior to historical SOC treatment. Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy.

Chemotherapy 145

Chemotherapy 145

European Pharmaceutical Review

OCTOBER 18, 2022

The process starts with chemoimmunotherapy, and if a patient responds to and can tolerate further treatment, they move on to high-dose chemotherapy (HDT) followed by a stem cell transplant (ASCT). 3 cytokine release syndrome (CRS) and neurologic events were observed in 6 percent and 21 percent of patients, respectively. months vs 2.0

Chemotherapy 111

Chemotherapy 111

pharmaphorum

MAY 5, 2021

months in patients with high PD-L1 expression compared with standard chemotherapy. Grade 3–4 treatment-related adverse events were reported in 12.9% of people receiving chemotherapy. Approval is based on Roche’s phase 3 Impower110 study which showed Tecentriq monotherapy improved overall survival by 7.1

Chemotherapy 98

Chemotherapy FDA 98

Pharmaceutical Technology

AUGUST 8, 2022

The latest approval is based on positive data from the multicentre, double-blind, randomised, placebo-controlled Phase III ARASENS clinical trial that analysed the safety and efficacy of oral darolutamide plus androgen deprivation therapy (ADT) and the chemotherapy docetaxel in mHSPC patients.

FDA 98

FDA Chemotherapy 98

PharmExec

OCTOBER 4, 2024

Approval for Opdivo was based on results from the CheckMate-77T trial, which demonstrated that the combination significantly improved event-free survival and pathologic complete response in adults with resectable non-small cell lung cancer without EGFR or ALK rearrangements.

Chemotherapy 52

Chemotherapy FDA 52

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings.

Chemotherapy 97

Chemotherapy Compounding Immunization 97

pharmaphorum

AUGUST 31, 2022

In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.

Chemotherapy 116

Chemotherapy Immunization Hospitals 116

pharmaphorum

SEPTEMBER 11, 2022

The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune responses to tumours, as well as immune-boosting cytokine interleukin-2, before the TILs are then reinfused into the patient intravenously.

Immunization 105

Immunization Chemotherapy Hospitals 105

pharmaphorum

FEBRUARY 11, 2021

The filing is based on findings of the innovaTV 204 phase 2 single-arm trial, in 101 patients with recurrent or metastatic disease previously treated with doublet chemotherapy and Roche’s Avastin (bevacizumab) if appropriate.

FDA 105

FDA Chemotherapy 105

Pharmaceutical Commerce

FEBRUARY 7, 2024

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.

Chemotherapy 52

Chemotherapy 52

PharmExec

FEBRUARY 7, 2024

Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful improvements in event-free survival in patients with resectable stage IIA to IIIB non-small cell lung cancer.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

FEBRUARY 15, 2021

The late stage data showed Padcev significantly improved overall survival compared with chemotherapy in a group of patients previously treated with platinum chemo and and a PD-1/L1 inhibitor. months in patients treated with Padcev compared with nine months in those treated with chemotherapy. months in the chemotherapy group.

Chemotherapy 69

Chemotherapy FDA 69

Pharmaceutical Technology

JUNE 4, 2023

Patients with resectable stage II, IIIA, and IIIB (T3-4N2) disease of both squamous and non-squamous histology were randomized to receive neoadjuvant Keytruda with platinum-based chemotherapy followed by adjuvant Keytruda, or placebo with platinum-based chemotherapy followed by placebo. At a median duration of follow-up of 25.2

Chemotherapy 75

Chemotherapy Hospitals FDA 75

pharmaphorum

JUNE 11, 2021

Now, results from the ongoing TRANSFORM study show that Breyanzi was more effective than the standard second-line treatment – salvage therapy followed by high-dose chemotherapy and a stem cell transplant – at fending off disease recurrence.

Chemotherapy 83

Chemotherapy Labelling FDA 83

European Pharmaceutical Review

MAY 3, 2023

Breyanzi Phase III trial results In the Phase III TRANSFORM trial , Breyanzi more than quadrupled median event-free survival (EFS) compared to standard therapy with a median follow-up of 6.2 Standard care was determined as salvage immunochemotherapy followed by high-dose chemotherapy and hematopoietic stem cell transplant (HSCT).

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

APRIL 12, 2023

The combined therapy includes toripalimab plus chemotherapy as peri-operative treatment and toripalimab monotherapy as consolidation therapy following adjuvant therapy. During the trial, patients with operable NSCLC were given toripalimab or a placebo along with platinum-based doublet chemotherapy as neoadjuvant and adjuvant therapy.

Chemotherapy 52

Chemotherapy Hospitals 52

pharmaphorum

FEBRUARY 11, 2022

The first-look data from the phase 1/2 trial revealed no drug-related serious adverse events, positive effects on IDUA biomarkers in the CNS, as well as preliminary evidence of improved neurodevelopment. With RGX-111, Regenxbio hopes to offer a one-shot treatment that delivers a functional copy of the IDUA gene to cells in the CNS.

Chemotherapy 111

Chemotherapy FDA 111

Pharmaceutical Technology

APRIL 4, 2023

The ORR and OS metrics surpassed the standard of care of gemcitabine plus nab-paclitaxel, and indicated potential complementary activity with the current standard chemotherapy regimen approved by the FDA.

Chemotherapy 59

Chemotherapy Compounding FDA 59

pharmaphorum

DECEMBER 13, 2021

In ZUMA-7, second-line treatment of relapsed or refractory LBCL patients with Yescarta extended median event-free survival (EFS) to 8.3 LBCL is the most common type of non-Hodgkin’s lymphoma (NHL) in adults, accounting for around a third of the 77,000 new cases diagnosed in the US.

Chemotherapy 98

Chemotherapy Labelling FDA 98

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy FDA Labelling Immunization 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

Event-free survival (EFS) was the primary endpoint in this study, with the neoadjuvant arm reporting a two-year EFS of 72% in comparison to the 49% reported for the adjuvant arm. Overall survival (OS) data remains immature, with too few events for statistical analysis. MSI-H/dMMR CRC accounts for 10-15% of all CRC.

Immunization 69

Immunization Chemotherapy 69

Hospital Pharmacy Europe

OCTOBER 20, 2023

The most common adverse event was cytokine release syndrome (CRS) (63%). Adverse events of grade 3 or higher occurred in 62% of the patients, with grade 3 or higher CRS in 4% and grade 3 or higher neurologic events in 3%. Discontinuation of glofitamab due to adverse events occurred in 9% of the patients.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

Hospital Pharmacy Europe

JANUARY 5, 2023

The first-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit or less intensive chemotherapy for less fit and transplant-ineligible individuals, although many eventually relapse with a progressive clinical course. Neurologic adverse events occurred in 15.4%

Chemotherapy 52

Chemotherapy Hospitals 52

IDStewardship

DECEMBER 26, 2022

As someone who enjoys the simplicity of Sesame Street and the complexity of Antimicrobial Chemotherapy, this one was near and dear to my heart as well as a long time coming. Assuming there are no major life events for our team in 2023, we should be in for a year of steady growth. EDITOR’S CHOICE: BEST ARTICLE OF 2022.

Chemotherapy 130

Chemotherapy Hospitals 130

Hospital Pharmacy Europe

DECEMBER 18, 2023

4,5 Polypharmacy – daily use of five or more drugs – is common in these patients and increases the risk of DRPs, which can result in adverse outcomes such as postoperative complications, chemotherapy toxicities and functional decline. 10,11 This can be due to side effects of chemotherapy or the addition of certain supportive care medications.

Chemotherapy 96

Chemotherapy Hospitals Communication Labelling 96

Pharmaceutical Technology

MAY 26, 2023

The study also evaluated VANFLYTA in combination with standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation. It enrolled 539 adult patients aged 18 to 75 years from 193 study sites across Asia, North America, Europe, Oceania and South America.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

DECEMBER 13, 2021

The AGILE trial, which compared the combination of Tibsovo (ivosidenib) and Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) to Vidaza plus placebo as a first-line therapy for IDH1-positive AML, showed a three-fold improvement in overall survival. for the Tibsovo are and 14.9% for the control group. for the control group.

Labelling 52

Labelling Chemotherapy 52

Hospital Pharmacy Europe

JULY 27, 2023

MOv18 IgE safety A total of 26 patients were enrolled and, overall, MOv18 IgE was generally well tolerated with the majority of adverse events being low grade. The most common events were localised cutaneous toxicities including urticaria, pruritus and rash, which appeared to be dose-related.

Chemotherapy 52

Chemotherapy Communication Hospitals 52

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. The majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile.

Immunization 84

Immunization Chemotherapy Medical Schools FDA 84

pharmaphorum

AUGUST 24, 2021

In the phase 3 BELINDA trial, Kymriah (tisagenlecleucel) was unable to extend event-free survival wen used as a second-line therapy for aggressive B-cell lymphoma, dashing Novartis’ hopes of extending its current use in patients who have relapsed after receiving two lines of therapy.

Chemotherapy 52

Chemotherapy Labelling 52

pharmaphorum

OCTOBER 1, 2021

Two months later, it missed the mark in another mid-stage study as a second-line monotherapy for biliary tract cancer (BTC), which was followed in August by a third failure as a first-line treatment alongside chemotherapy in locally advanced or metastatic BTC. billion takeover of Tesaro in 2019.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

JUNE 12, 2022

CTX001 treatment has its limitations, however, not least that patient have to undergo myeloablative chemotherapy with a busulfan-based regimen followed by transplant with the CRISPR-modified cells back into the bone marrow. There have also ben no cases of cancer – a concern with bluebird’s gene therapy approach.

Chemotherapy 59

Chemotherapy FDA 59

pharmaphorum

NOVEMBER 29, 2022

Those immunologically cold gastrointestinal tumours present a real clinical challenge, with a standard of care heavily relying on chemotherapy approaches. No serious adverse events were observed. It is worth noting that patients with r/r PaC or r/r MSS-CRC have very limited treatment options.

Immunization 105

Immunization Chemotherapy Compounding FDA 105